Max Crispin

List of Publications by Year in Descending Order

181 papers	9,790 citations	54 h-index	95 g-index
201 ext. papers	12,480 ext. citations	9.9 avg, IF	6.56 L-index

#	Paper	IF	Citations
181	Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.. *Cell Reports*, **2022**, 110318	10.6	2
180	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers.. *Npj Vaccines*, **2022**, 7, 27	9.5	1
179	Principles of SARS-CoV-2 Glycosylation. *Current Opinion in Structural Biology*, **2022**, 102402	8.1	0
178	The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization. *Journal of Virology*, **2021**, JVI0155221	6.6	2
177	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. *PLoS Pathogens*, **2021**, 17, e1009807	7.6	1
176	Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints. *Analytical Chemistry*, **2021**, 93, 14392-14400	7.8	4
175	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. *Journal of Molecular Biology*, **2021**, 434, 167332	6.5	1
174	A cross-neutralizing antibody between HIV-1 and influenza virus. *PLoS Pathogens*, **2021**, 17, e1009407	7.6	9
173	Site-specific steric control of SARS-CoV-2 spike glycosylation **2021**,		3
172	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. *Cell*, **2021**, 184, 1188-1200.e19	56.2	68
171	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. *Science Translational Medicine*, **2021**, 13,	17.5	13
170	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. *ACS Central Science*, **2021**, 7, 594-602	16.8	47
169	SARS-CoV-2-specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi-System Syndrome. *Pediatric Allergy and Immunology*, **2021**, 32, 1125-1129	4.2	4
168	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. *Cell Reports*, **2021**, 35, 108933	10.6	11
167	Clinical significance of crown-like structures to trastuzumab response in patients with primary invasive HER2+ breast cancer.. *Journal of Clinical Oncology*, **2021**, 39, e12533-e12533	2.2	
166	Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. *Immunology*, **2021**, 164, 135-147	7.8	10
165	TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. *Communications Biology*, **2021**, 4, 772	6.7	4

164	Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. *MBio*, **2021**, 12, e0042921	7.8	1
163	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. *Biochemistry*, **2021**, 60, 2153-2169	3.2	20
162	Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients. *Journal of Immunological Methods*, **2021**, 494, 113046	2.5	18
161	Identification of N-glycans with GalNAc-containing antennae from recombinant HIV trimers by ion mobility and negative ion fragmentation. *Analytical and Bioanalytical Chemistry*, **2021**, 413, 7229-7240	4.4	1
160	A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. *Nature Genetics*, **2021**, 53, 205-214	36.3	64
159	Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine **2021**,		13
158	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. *Npj Vaccines*, **2021**, 6, 24	9.5	8
157	Subtle Influence of ACE2 Glycan Processing on SARS-CoV-2 Recognition. *Journal of Molecular Biology*, **2021**, 433, 166762	6.5	30
156	Site-Specific Glycosylation of Recombinant Viral Glycoproteins Produced in. *Frontiers in Plant Science*, **2021**, 12, 709344	6.2	3
155	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. *Blood*, **2021**, 138, 1570-1582	2.2	1
154	Formation and fragmentation of doubly and triply charged ions in the negative ion spectra of neutral N-glycans from viral and other glycoproteins. *Analytical and Bioanalytical Chemistry*, **2021**, 413, 7277-7294	4.4	
153	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. *Nature Communications*, **2021**, 12, 4817	17.4	8
152	Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response. *BMJ Open Respiratory Research*, **2021**, 8,	5.6	7
151	Site-specific glycan analysis of the SARS-CoV-2 spike. *Science*, **2020**, 369, 330-333	33.3	768
150	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. *Nature Communications*, **2020**, 11, 2688	17.4	174
149	Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. *Structure*, **2020**, 28, 897-909.e6	5.2	24
148	Site-specific analysis of the SARS-CoV-2 glycan shield **2020**,		74
147	Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome **2020**,		17

146	Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection **2020**,		41
145	Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response **2020**,		8
144	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. *Journal of Virology*, **2020**, 94,	6.6	7
143	Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples. *Emerging Infectious Diseases*, **2020**, 26, 2970-2973	10.2	37
142	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. *PLoS Pathogens*, **2020**, 16, e1008665	7.6	25
141	Molecular Architecture of the SARS-CoV-2 Virus. *Cell*, **2020**, 183, 730-738.e13	56.2	385
140	SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. *Thorax*, **2020**, 75, 1089-1094	7.3	144
139	A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding. *Frontiers in Plant Science*, **2020**, 11, 609207	6.2	6
138	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
137	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
136	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
135	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens **2020**, 16, e1008665		
134	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. *Nature Communications*, **2019**, 10, 4272	17.4	80
133	Exploitation of glycosylation in enveloped virus pathobiology. *Biochimica Et Biophysica Acta - General Subjects*, **2019**, 1863, 1480-1497	4	228
132	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. *Nature Communications*, **2019**, 10, 2355	17.4	68
131	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. *Cell Reports*, **2019**, 27, 2426-2441.e6	10.6	20
130	Protein and Glycan Mimicry in HIV Vaccine Design. *Journal of Molecular Biology*, **2019**, 431, 2223-2247	6.5	55
129	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. *PLoS Pathogens*, **2019**, 15, e1007920	7.6	41

128	Mannosylation of the Tumor Immunoglobulin Variable Region Informs Cell of Origin and Environmental Interactions in DLBCL Subsets. *Blood*, **2019**, 134, 1505-1505	2.2	1
127	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. *Immunity*, **2019**, 51, 915-929.e7	32.3	62
126	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. *Science*, **2019**, 363, 649-654	33.3	138
125	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. *Journal of Virology*, **2019**, 93,	6.6	50
124	Isomer Information from Ion Mobility Separation of High-Mannose Glycan Fragments. *Journal of the American Society for Mass Spectrometry*, **2018**, 29, 972-988	3.5	14
123	Collision Cross Sections and Ion Mobility Separation of Fragment Ions from Complex N-Glycans. *Journal of the American Society for Mass Spectrometry*, **2018**, 29, 1250-1261	3.5	20
122	Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. *Cell Reports*, **2018**, 23, 90-99	10.6	45
121	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. *Journal of Proteome Research*, **2018**, 17, 987-999	5.6	18
120	Quantitative mass imaging of single biological macromolecules. *Science*, **2018**, 360, 423-427	33.3	209
119	Structure and Immune Recognition of the HIV Glycan Shield. *Annual Review of Biophysics*, **2018**, 47, 499-523	22.1	81
118	Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage. *Frontiers in Immunology*, **2018**, 9, 1631	8.4	24
117	Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. *Frontiers in Immunology*, **2018**, 9, 1116	8.4	19
116	Structural analysis of glycoproteins: building N-linked glycans with Coot. *Acta Crystallographica Section D: Structural Biology*, **2018**, 74, 256-263	5.5	50
115	Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. *Cell Reports*, **2018**, 24, 1958-1966.e5	10.6	89
114	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. *Biotechnology and Bioengineering*, **2018**, 115, 885-899	4.9	56
113	HIV-1 vaccine design through minimizing envelope metastability. *Science Advances*, **2018**, 4, eaau6769	14.3	43
112	Cryo-EM Structures of Eastern Equine Encephalitis Virus Reveal Mechanisms of Virus Disassembly and Antibody Neutralization. *Cell Reports*, **2018**, 25, 3136-3147.e5	10.6	25
111	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. *Cell Reports*, **2018**, 24, 3324-3338.e5	10.6	33

110	Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. *Glycobiology*, **2018**, 28, 697-712	5.8	6
109	Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. *Nature Communications*, **2018**, 9, 1956	17.4	28
108	Harnessing post-translational modifications for next-generation HIV immunogens. *Biochemical Society Transactions*, **2018**, 46, 691-698	5.1	2
107	Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding. *Analytical Chemistry*, **2018**, 90, 7325-7331	7.8	22
106	Structure of the Lassa virus glycan shield provides a model for immunological resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 7320-7325	11.5	62
105	Identification of Lewis and Blood Group Carbohydrate Epitopes by Ion Mobility-Tandem-Mass Spectrometry Fingerprinting. *Analytical Chemistry*, **2017**, 89, 2318-2325	7.8	44
104	The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans. *Structure*, **2017**, 25, 773-782.e5	5.2	28
103	Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. *BioDrugs*, **2017**, 31, 151-166	6.9	42
102	Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy. *Molecular Cancer Therapeutics*, **2017**, 16, 1887-1897	6.1	4
101	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. *Journal of Virology*, **2017**, 91,	6.6	33
100	Structural principles controlling HIV envelope glycosylation. *Current Opinion in Structural Biology*, **2017**, 44, 125-133	8.1	61
99	Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry. *ACS Chemical Biology*, **2017**, 12, 357-361	4.9	27
98	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. *Cell Reports*, **2017**, 21, 222-235	10.6	40
97	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. *Cell Reports*, **2017**, 20, 1805-1817	10.6	112
96	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. *Journal of Experimental Medicine*, **2017**, 214, 2573-2590	16.6	100
95	Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. *Expert Review of Proteomics*, **2017**, 14, 881-890	4.2	18
94	Manipulation of cytokine secretion in human dendritic cells using glycopolymers with picomolar affinity for DC-SIGN. *Chemical Science*, **2017**, 8, 6974-6980	9.4	23
93	Immunoglobulin G Fc glycans are not essential for antibody-mediated immune suppression to murine erythrocytes. *Blood*, **2017**, 130, 2902-2905	2.2	1

92	Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 7031-7036	11.5	23
91	Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. *Journal of Virology*, **2017**, 91,	6.6	56
90	CHAPTER 11:Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. *Chemical Biology* , **2017**, 300-357	0.4	3
89	Travelling-wave ion mobility mass spectrometry and negative ion fragmentation of hybrid and complex N-glycans. *Journal of Mass Spectrometry*, **2016**, 51, 1064-1079	2.2	26
88	Structure of a phleboviral envelope glycoprotein reveals a consolidated model of membrane fusion. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 7154-9	11.5	54
87	Native functionality and therapeutic targeting of arenaviral glycoproteins. *Current Opinion in Virology*, **2016**, 18, 70-5	7.5	11
86	Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. *Retrovirology*, **2016**, 13, 8	3.6	26
85	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. *Cell Reports*, **2016**, 14, 2695-706	10.6	193
84	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. *Nature Microbiology*, **2016**, 2, 16199	26.6	103
83	Travelling-wave ion mobility and negative ion fragmentation of high-mannose N-glycans. *Journal of Mass Spectrometry*, **2016**, 51, 219-35	2.2	32
82	HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. *Journal of Virology*, **2016**, 90, 11132-11144	6.6	29
81	Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. *Biochimica Et Biophysica Acta - General Subjects*, **2016**, 1860, 1655-68	4	35
80	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. *Cell*, **2016**, 165, 813-26	56.2	301
79	Antibody production using a ciliate generates unusual antibody glycoforms displaying enhanced cell-killing activity. *MAbs*, **2016**, 8, 1498-1511	6.6	10
78	A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. *Journal of Immunological Methods*, **2015**, 417, 34-44	2.5	64
77	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. *Nature Communications*, **2015**, 6, 7479	17.4	97
76	Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. *Journal of Virology*, **2015**, 89, 6952-9	6.6	31
75	Eliminating antibody polyreactivity through addition of N-linked glycosylation. *Protein Science*, **2015**, 24, 1019-30	6.3	8

74	Breaking the allergic response by disrupting antibody glycosylation. *Journal of Experimental Medicine*, **2015**, 212, 433	16.6	2
73	Ion Mobility Mass Spectrometry for Ion Recovery and Clean-Up of MS and MS/MS Spectra Obtained from Low Abundance Viral Samples. *Journal of the American Society for Mass Spectrometry*, **2015**, 26, 1754-67	3.5	25
72	Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor. *Molecular Immunology*, **2015**, 68, 234-43	4.3	4
71	Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. *Journal of Virology*, **2015**, 89, 8932-44	6.6	72
70	Determination of N-linked Glycosylation in Viral Glycoproteins by Negative Ion Mass Spectrometry and Ion Mobility. *Methods in Molecular Biology*, **2015**, 1331, 93-121	1.4	9
69	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. *Journal of Virology*, **2015**, 89, 12189-210	6.6	66
68	A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. *Transfusion*, **2015**, 55, 1501-11	2.9	9
67	Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. *Biomolecules*, **2015**, 5, 2919-34	5.9	9
66	Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. *Current Opinion in Virology*, **2015**, 11, 63-9	7.5	60
65	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. *Cell*, **2015**, 163, 1702-15	56.2	251
64	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. *Cell Reports*, **2015**, 11, 1604-13	10.6	101
63	Glycan Remodeling with Processing Inhibitors and Lectin-Resistant Eukaryotic Cells. *Methods in Molecular Biology*, **2015**, 1321, 307-22	1.4	4
62	Emerging principles for the therapeutic exploitation of glycosylation. *Science*, **2014**, 343, 1235681	33.3	329
61	Structural plasticity of the Semliki Forest virus glycome upon interspecies transmission. *Journal of Proteome Research*, **2014**, 13, 1702-12	5.6	23
60	Fragmentation of negative ions from N-linked carbohydrates: part 6. Glycans containing one N-acetylglucosamine in the core. *Rapid Communications in Mass Spectrometry*, **2014**, 28, 2008-18	2.2	25
59	Uukuniemi Phlebovirus assembly and secretion leave a functional imprint on the virion glycome. *Journal of Virology*, **2014**, 88, 10244-51	6.6	22
58	Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. *Aids*, **2014**, 28, 2523-30	3.5	84
57	Fragments of bacterial endoglycosidase s and immunoglobulin g reveal subdomains of each that contribute to deglycosylation. *Journal of Biological Chemistry*, **2014**, 289, 13876-89	5.4	18

56	Antibody Glycosylation **2014**, 179-194		2
55	HIV Glycomics and Glycoproteomics **2014**, 1-25		1
54	Travelling wave ion mobility and negative ion fragmentation for the structural determination of N-linked glycans. *Electrophoresis*, **2013**, 34, 2368-78	3.6	49
53	Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. *Journal of Molecular Biology*, **2013**, 425, 1253-8	6.5	100
52	Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. *Journal of the American Chemical Society*, **2013**, 135, 9723-32	16.4	71
51	Solution NMR analyses of the C-type carbohydrate recognition domain of DC-SIGNR protein reveal different binding modes for HIV-derived oligosaccharides and smaller glycan fragments. *Journal of Biological Chemistry*, **2013**, 288, 22745-57	5.4	13
50	Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E3544-6	11.5	73
49	Directing stem cell differentiation with antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 17608-9	11.5	4
48	Therapeutic potential of deglycosylated antibodies. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 10059-60	11.5	7
47	Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. *Journal of Clinical Investigation*, **2013**, 123, 2183-92	15.9	233
46	MALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans. *Journal of the American Society for Mass Spectrometry*, **2012**, 23, 1955-66	3.5	49
45	Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. *Journal of the American Chemical Society*, **2012**, 134, 17554-63	16.4	62
44	Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions. *Journal of Molecular Biology*, **2012**, 420, 1-7	6.5	47
43	An endoglycosidase with alternative glycan specificity allows broadened glycoprotein remodelling. *Journal of the American Chemical Society*, **2012**, 134, 8030-3	16.4	105
42	The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. *PLoS ONE*, **2011**, 6, e23521	3.7	182
41	A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. *Science*, **2011**, 334, 1097-103	33.3	576
40	Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120. *Journal of the American Society for Mass Spectrometry*, **2011**, 22, 568-81	3.5	61
39	Use of the Emannosidase I inhibitor kifunensine allows the crystallization of apo CTLA-4 homodimer produced in long-term cultures of Chinese hamster ovary cells. *Acta Crystallographica Section F: Structural Biology Communications*, **2011**, 67, 785-9		14

38	Dimeric architecture of the Hendra virus attachment glycoprotein: evidence for a conserved mode of assembly. *Journal of Virology*, **2010**, 84, 6208-17	6.6	75
37	Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 13800-5	11.5	275
36	Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. *Glycobiology*, **2010**, 20, 812-23	5.8	67
35	Solutions to the Glycosylation Problem for Low- and High-Throughput Structural Glycoproteomics **2010**, 127-158		3
34	Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies. *Biochemical Society Transactions*, **2010**, 38, 1349-55	5.1	28
33	A human embryonic kidney 293T cell line mutated at the Golgi alpha-mannosidase II locus. *Journal of Biological Chemistry*, **2009**, 284, 21684-95	5.4	33
32	Unusual molecular architecture of the machupo virus attachment glycoprotein. *Journal of Virology*, **2009**, 83, 8259-65	6.6	63
31	Identification of high-mannose and multiantennary complex-type N-linked glycans containing alpha-galactose epitopes from Nurse shark IgM heavy chain. *Glycoconjugate Journal*, **2009**, 26, 1055-64	3	11
30	Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. *Journal of Molecular Biology*, **2009**, 387, 1061-6	6.5	63
29	Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. *Journal of Virology*, **2008**, 82, 11628-36	6.6	89
28	Differentiation between isomeric triantennary N-linked glycans by negative ion tandem mass spectrometry and confirmation of glycans containing galactose attached to the bisecting (beta1-4-GlcNAc) residue in N-glycans from IgG. *Rapid Communications in Mass Spectrometry*, **2008**, 22, 1047-52	2.2	43
27	Analysis of variable N-glycosylation site occupancy in glycoproteins by liquid chromatography electrospray ionization mass spectrometry. *Analytical Biochemistry*, **2007**, 361, 149-51	3.1	11
26	Building meaningful models of glycoproteins. *Nature Structural and Molecular Biology*, **2007**, 14, 354; discussion 354-5	17.6	41
25	Glycoprotein structural genomics: solving the glycosylation problem. *Structure*, **2007**, 15, 267-73	5.2	234
24	Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. *Journal of Molecular Biology*, **2007**, 372, 16-22	6.5	66
23	Disruption of alpha-mannosidase processing induces non-canonical hybrid-type glycosylation. *FEBS Letters*, **2007**, 581, 1963-8	3.8	17
22	Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. *Glycobiology*, **2006**, 16, 748-56	5.8	50
21	Molecular mechanism of lipopeptide presentation by CD1a. *Immunity*, **2005**, 22, 209-19	32.3	112

20	The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin. *Journal of Immunology*, **2004**, 173, 6831-40	5.3	87
19	Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. *FEBS Letters*, **2004**, 566, 270-4	3.8	42
18	The carbohydrate moiety of serum IgM from Atlantic cod (Gadus morhua L.). *Fish and Shellfish Immunology*, **2002**, 12, 209-27	4.3	16
17	Contrasting IgG structures reveal extreme asymmetry and flexibility. *Journal of Molecular Biology*, **2002**, 319, 9-18	6.5	209
16	Molecular Architecture of the SARS-CoV-2 Virus. *SSRN Electronic Journal*,	1	2
15	Chimpanzee SIV Envelope trimer: structure and deployment as an HIV vaccine template		1
14	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics		1
13	Networks of HIV-1 envelope glycans maintain antibody epitopes in the face of glycan additions and deletions		2
12	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens		4
11	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation		13
10	SARS-CoV-2 seroconversion in health care workers		23
9	Sensitive detection of SARS-CoV-2-specific-antibodies in dried blood spot samples		1
8	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike		6
7	Molecular architecture of the SARS-CoV-2 virus		10
6	A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection		9
5	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection		1
4	Quantitative mass imaging of single molecules in solution		2
3	Stimulation of vascular organoids with SARS-CoV-2 antigens increases endothelial permeability and regulates vasculopathy		1

2	Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein	3
1	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM	1